传染病信息
傳染病信息
전염병신식
INFECTIOUS DISEASE INFORMATION
2014年
2期
100-102
,共3页
乙型肝炎,慢性%抗病毒药%安全%治疗结果%病例对照研究
乙型肝炎,慢性%抗病毒藥%安全%治療結果%病例對照研究
을형간염,만성%항병독약%안전%치료결과%병례대조연구
hepatitis B,chronic%antiviral agents%safety%treatment outcome%case-control studies
目的：观察恩替卡韦联合六味五灵片治疗慢性乙型肝炎（chronic hepatitis B, CHB）的疗效和安全性。方法选择本院2010年7月-2011年7月门诊和住院CHB患者81例，将其分为联合用药组（41例）和对照组（40例）。给予联合用药组恩替卡韦联合六味五灵片治疗，给予对照组恩替卡韦治疗。治疗期间每月随访记录症状、体征和不良反应，治疗前及治疗第3、6、12个月分别检测HBsAg、HBeAg、HBV DNA、血常规和肝肾功能。结果联合用药组HBeAg转阴率、HBeAb转阳率、HBV DNA转阴率和ALT复常率均显著高于对照组，差异有统计学意义。2组均未出现过敏反应和肾损伤。联合用药组1例和对照组2例出现头晕和腹部不适等，均不影响治疗。结论恩替卡韦联合六味五灵片治疗CHB，能快速、强效地抑制HBV复制，安全性和耐受性良好，较单用恩替卡韦疗效好，但尚须今后进一步研究验证。
目的：觀察恩替卡韋聯閤六味五靈片治療慢性乙型肝炎（chronic hepatitis B, CHB）的療效和安全性。方法選擇本院2010年7月-2011年7月門診和住院CHB患者81例，將其分為聯閤用藥組（41例）和對照組（40例）。給予聯閤用藥組恩替卡韋聯閤六味五靈片治療，給予對照組恩替卡韋治療。治療期間每月隨訪記錄癥狀、體徵和不良反應，治療前及治療第3、6、12箇月分彆檢測HBsAg、HBeAg、HBV DNA、血常規和肝腎功能。結果聯閤用藥組HBeAg轉陰率、HBeAb轉暘率、HBV DNA轉陰率和ALT複常率均顯著高于對照組，差異有統計學意義。2組均未齣現過敏反應和腎損傷。聯閤用藥組1例和對照組2例齣現頭暈和腹部不適等，均不影響治療。結論恩替卡韋聯閤六味五靈片治療CHB，能快速、彊效地抑製HBV複製，安全性和耐受性良好，較單用恩替卡韋療效好，但尚鬚今後進一步研究驗證。
목적：관찰은체잡위연합륙미오령편치료만성을형간염（chronic hepatitis B, CHB）적료효화안전성。방법선택본원2010년7월-2011년7월문진화주원CHB환자81례，장기분위연합용약조（41례）화대조조（40례）。급여연합용약조은체잡위연합륙미오령편치료，급여대조조은체잡위치료。치료기간매월수방기록증상、체정화불량반응，치료전급치료제3、6、12개월분별검측HBsAg、HBeAg、HBV DNA、혈상규화간신공능。결과연합용약조HBeAg전음솔、HBeAb전양솔、HBV DNA전음솔화ALT복상솔균현저고우대조조，차이유통계학의의。2조균미출현과민반응화신손상。연합용약조1례화대조조2례출현두훈화복부불괄등，균불영향치료。결론은체잡위연합륙미오령편치료CHB，능쾌속、강효지억제HBV복제，안전성화내수성량호，교단용은체잡위료효호，단상수금후진일보연구험증。
Objective To evaluate the efficacy and safety of entecavir combined with Liuweiwuling tablets in the treatment of chronic hepatitis B (CHB). Methods A total of 81 CHB outpatients or hospitalized patients treated in our hospital from Jul. 2010 to Jul. 2011 were randomly divided into a combination group (n=41) and a control group (n=40). The combination group was treated with entecavir combined with Liuweiwuling tablets, while the control group was given entecavir alone. Clinical symptoms, signs and adverse reactions were recorded monthly during the treatment, and HBsAg, HBeAg, HBV DNA, blood routine and liver-kidney function were detected before treatment and at 3-, 6- and 12-month of treatment, respectively. Results The HBeAg negative con-version rate, HBeAb positive conversion rate, HBV DNA negative conversion rate and ALT normalization rate of the combination group were significantly higher than those of the control group, and the differences between the two groups were significant. No aller-gic reaction and kidney injury were found in the two groups. Dizziness, abdominal discomfort and other adverse reactions occurred in one patient in the combination group and 2 patients in the control group, but had no effect on the treatment. Conclusions Ente-cavir combined with Liuweiwuling tablets can quickly and effectively suppress HBV replication in CHB patients. The combination medication is safe and well tolerated. The therapeutic efficacy of entecavir combined with Liuweiwuling tablets is better than that of entecavir alone, but needs further study to verify.
